RenaissanceNCT05076682
Reverse Triple Negative Immune Resistant Breast Cancer
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 7 versions: 7 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 17 words Show 6 more changesShow less
- Enrollment increased: 80 → 90 participants
- Interventions modified
- Trial arms changed: 8 → 9
- Secondary endpoints: details revised at 1 of 6 entries
- Publications: details revised at 1 of 1 entry
- Study description expanded, about 3 words
- Minor Enrollment target: 70 to 80
- Interventions: AK131 (Drug), Choline (Drug), Efavirenz (Drug), Mecapegfilgrastim (Drug), SHR-1316 (Drug), SHR-A1811 (Drug), SHR-A2102 (Drug), Sodium… to AK131 (Drug), Choline (Drug), Efavirenz (Drug), Mecapegfilgrastim (Drug), SHR-1316 (Drug), SHR-A1811 (Drug), SHR-A2102 (Drug), Sodium…
- Study arms: 7 to 8
- Study description expanded, about 2 words
Notable Enrollment target: 30 to 70v5 Show 7 more changesShow less
- Primary completion date: Dec 2022 to Dec 31, 2026
- Eligibility criteria expanded, about 13 words
- Study completion date: Mar 2023 to Mar 31, 2027
- Interventions: Choline (Drug), Efavirenz (Drug), Sodium Cromoglicate (Drug), anti-PD-1 antibody and chemotherapy (Drug) to AK131 (Drug), Choline (Drug), Efavirenz (Drug), Mecapegfilgrastim (Drug), SHR-1316 (Drug), SHR-A1811 (Drug), SHR-A2102 (Drug), Sodium…
- Secondary endpoints: details revised at 2 of 6 entries
- Study description shortened, about 83 words
- Study arms: 3 to 7
Notable Enrollment target: 20 to 30v4 Show 4 more changesShow less
- Interventions: Sodium Cromoglicate (Drug), anti-PD-1 antibody and chemotherapy (Drug), choline (Drug) to Choline (Drug), Efavirenz (Drug), Sodium Cromoglicate (Drug), anti-PD-1 antibody and chemotherapy (Drug)
- Secondary endpoints: 4 to 6
- Study description expanded, about 46 words
- Study arms: 2 to 3
- Minor Start date changed from estimate of Apr 2022 to Jun 30, 2022v3
Notable Start date: Oct 15, 2021 to Apr 2022v2 Show 6 more changesShow less
- Primary endpoints: 1 to 2
- Primary completion date: Oct 15, 2022 to Dec 2022
- Study completion date: Dec 31, 2022 to Mar 2023
- Interventions: PD-1 inhibitor and chemo (Drug), Sodium Cromoglicate (Drug), choline (Drug) to Sodium Cromoglicate (Drug), anti-PD-1 antibody and chemotherapy (Drug), choline (Drug)
- Secondary endpoints: 3 to 4
- Study description expanded, about 1 word
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Objective Response Rate (ORR)
Timeframe: Baseline until disease progression or loss of clinical benefit, assessed up to 6 months
Immune changes in peripheral blood
Timeframe: Baseline until disease progression or loss of clinical benefit, assessed up to 6 months
Secondary (6)
Disease Control Rate (DCR)
Progression Free Survival (PFS)
Safety and treatment-related AEs
Biomarker analysis1
Biomarker analysis2
Show 1 moreShow less
Biomarker analysis3
Arms and interventions
CholineExperimental
Choline with anti-PD-1 immunotherapy
Sodium cromoglicateExperimental
Sodium cromoglicate with anti-PD-1 immunotherapy
EfavirenzExperimental
Efavirenz with anti-PD-1 immunotherapy
HER2 lowExperimental
HER2 low expression
HER2 0Experimental
HER2 0 expression
AK131Experimental
AK131(CD73/PD1 bispecific antibody)
MecapegfilgrastimExperimental
Mecapegfilgrastim with anti-PD-1 immunotherapy
TheophyllineExperimental
Theophylline with anti-PD-1 immunotherapy
MifepristoneExperimental
Mifepristone with anti-PD-1 immunotherapy
Drugs: Choline, anti-PD-1 antibody and chemotherapy, Sodium Cromoglicate, Efavirenz, SHR-A1811, SHR-A2102, SHR-1316, Mecapegfilgrastim, AK131, Theophylline, Mifepristone
Sites
1 site in 1 country
- Fudan University Shanghai Cancer CenterShanghai, China